These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36112929)

  • 1. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
    Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
    J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
    Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical Features and Prognosis of Patients with CD5
    Huang XJ; Yang J; Wei XF; Fu Y; Zhao YY; Cheng MX; Li QF; Yan HL; Feng YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):750-755. PubMed ID: 38926962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De Novo CD5
    Xu Y; Sun W; Li F
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.
    Sang W; Ma Y; Wang X; Ma Y; Shen Z; Gu W; Wang F; Ye J; Zhang C; Miao Y; Xu C; Liu Q; Li B; Tu J; Wang C; Shi Y; Sun S; Yan D; Song X; Sun C; Shao Y; Xu L; Li Z; Ma D; Xu K; Young KH; Liu H
    Am J Surg Pathol; 2022 Nov; 46(11):1533-1544. PubMed ID: 36006771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
    Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
    Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
    Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
    Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 14. CD5
    Lu TX; Wu S; Zhou XY; Zhang Y; Hong TT; Cai DY; Hua HY; Qi XW; Wu XH
    Exp Mol Pathol; 2020 Feb; 112():104326. PubMed ID: 31706988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
    Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
    Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
    Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
    Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
    Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
    Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.